UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 11-K
FOR ANNUAL REPORTS OF
EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS
PURSUANT TO SECTION 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
(MARK ONE)
☒ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2019
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM ______________
TO ____________
COMMISSION FILE NUMBER 001-09974
Enzo Biochem, Inc.
Salary Reduction Profit Sharing Plan
(Full title of the plan and the address
of the plan, if different from that of the issuer named below:)
Enzo Biochem, Inc. 527 Madison Ave. New
York, NY 10022
(Name of issuer of the securities held
pursuant to the plan and the address of its principal executive office)
ENZO BIOCHEM, INC.
SALARY REDUCTION PROFIT SHARING PLAN
Table of Contents
REPORT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM
To the Plan Administrator, Participants
and Beneficiaries
of the Enzo Biochem, Inc. Salary Reduction
Profit Sharing Plan
Opinion on the Financial Statements
We have audited the accompanying statements
of net assets available for benefits of the Enzo Biochem, Inc. Salary Reduction Profit Sharing Plan (the “Plan”) as
of December 31, 2019 and 2018, and the related statement of changes in net assets available for benefits for the year ended December
31, 2019, and the related notes (collectively the “financial statements”). In our opinion, the financial statements
present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2019 and 2018, and
the changes in net assets available for benefits for the year ended December 31, 2019, in conformity with accounting principles
generally accepted in the United States of America.
Basis for Opinion
These financial statements are the responsibility
of the Plan’s management. Our responsibility is to express an opinion on the Plan’s financial statements based on our audits.
We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”)
and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with
the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether
the financial statements are free of material misstatement, whether due to error or fraud. The Plan is not required to have, nor
were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to
obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness
of the Plan’s internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures
to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures
in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made
by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a
reasonable basis for our opinion.
Report on Supplemental Information
The supplemental information in the accompanying
schedule of assets (held at end of year) as of December 31, 2019 has been subjected to audit procedures performed in conjunction
with the audit of the Plan’s financial statements. The supplemental information is the responsibility of the Plan’s management.
Our audit procedures included determining whether the supplemental information reconciles to the financial statements or the underlying
accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information
presented in the supplemental information. In forming our opinion on the supplemental information, we evaluated whether the supplemental
information, including its form and content, is presented in conformity with the Department of Labor’s Rules and Regulations for
Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the supplemental information
is fairly stated, in all material respects, in relation to the financial statements as a whole.
/s/ EisnerAmper LLP
We have served as the Plan’s auditor
since 2010.
EISNERAMPER LLP
New York, NY
August 12, 2020
ENZO BIOCHEM, INC.
SALARY REDUCTION PROFIT SHARING PLAN
Statements of Net Assets Available for
Benefits
December 31,
|
|
|
2019
|
|
|
2018
|
|
|
ASSETS
|
|
|
|
|
|
|
|
Investments, at fair value:
|
|
|
|
|
|
|
|
Mutual funds
|
|
$
|
32,523,374
|
|
|
$
|
26,750,617
|
|
|
Enzo Biochem, Inc. common stock
|
|
|
2,961,454
|
|
|
|
2,516,906
|
|
|
|
|
|
35,484,828
|
|
|
|
29,267,523
|
|
|
Receivables:
|
|
|
|
|
|
|
|
|
|
Employer’s contributions
|
|
|
836,494
|
|
|
|
829,689
|
|
|
Participants’ contributions
|
|
|
-
|
|
|
|
66,885
|
|
|
Notes receivable – participants
|
|
|
766,493
|
|
|
|
660,890
|
|
|
|
|
|
1,602,987
|
|
|
|
1,557,464
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL ASSETS
|
|
|
37,087,815
|
|
|
|
30,824,987
|
|
|
|
|
|
|
|
|
|
|
|
|
NET ASSETS AVAILABLE FOR BENEFITS
|
|
$
|
37,087,815
|
|
|
$
|
30,824,987
|
|
See notes to financial statements.
ENZO BIOCHEM, INC.
SALARY REDUCTION PROFIT SHARING PLAN
Statement of Changes in Net Assets Available
for Benefits
For the Year Ended December 31, 2019
|
|
|
|
|
|
Additions (deductions) from net assets attributed to:
|
|
|
|
|
Investment income:
|
|
|
|
|
Interest and dividends
|
|
$
|
1,686,153
|
|
|
Net realized/unrealized appreciation in value of investments
|
|
|
4,286,583
|
|
|
Interest on notes receivable - participants
|
|
|
35,303
|
|
|
Contributions:
|
|
|
|
|
|
Participants’ contributions
|
|
|
2,280,301
|
|
|
Employer’s contributions
|
|
|
836,494
|
|
|
Benefits paid to participants
|
|
|
(2,786,294
|
)
|
|
Administrative expenses
|
|
|
(75,712
|
)
|
|
Net increase in net assets available for benefits
|
|
|
6,262,828
|
|
|
|
|
|
|
|
|
Net assets available for benefits, beginning of year
|
|
|
30,824,987
|
|
|
|
|
|
|
|
|
Net assets available for benefits, end of year
|
|
$
|
37,087,815
|
|
See notes to financial statements.
ENZO BIOCHEM, INC.
SALARY REDUCTION PROFIT SHARING PLAN
Notes to Financial Statements
|
NOTE 1:
|
PLAN DESCRIPTION
|
|
|
|
|
|
The following description of the Enzo Biochem, Inc. Salary Reduction Profit Sharing Plan (the “Plan”) provides only general information. Participants should refer to the Plan Agreement, as amended, for a more complete description of the Plan’s provisions.
|
|
|
|
|
|
General
|
|
|
|
|
|
The Plan is a defined contribution plan covering all eligible United States based full-time employees of Enzo Biochem, Inc., (the “Plan Sponsor”), and its wholly owned subsidiaries, Enzo Clinical Labs, Inc., Enzo Therapeutics, Inc., and Enzo Life Sciences, Inc. (collectively, the “Company”) who have completed one month of service and have attained age twenty-one. The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974 (“ERISA”).
|
|
|
|
|
|
Contributions
|
|
|
|
|
|
Eligible employee participants can elect to defer up to 70% of compensation to the maximum amount permitted by the Internal Revenue Code (the “Code”) for each year ($19,000 in 2019 and $18,500 in 2018). Catch-up contributions are also permitted for participants who have attained age 50 by December 31st, in accordance with Section 414(v) of the Code, in an amount up to a maximum of $6,000 in 2019 and 2018, bringing those participants’ statutory maximum limitation to $25,000 in 2019 and $24,500 in 2018. In 2019, participant contributions totaled $2,280,301 which includes $47,863 in rollover contributions.
|
|
|
|
|
|
The Company may contribute to the Plan annually, a discretionary matching contribution and a non-elective employer contribution. For 2019 and 2018 the discretionary matching contribution was equal to 50% of the participant’s 401(k) contribution, not to exceed 5% of the participant’s annual compensation, as defined. Participants who have completed 1,000 hours of service during the plan year and are actively employed as of the last day of the plan year shall be deemed eligible to share in the matching contribution or the non-elective employer contribution for the year. In 2019, the total matching contributions were $836,494 in the form of Enzo Biochem Inc. common stock. There were no non-elective employer contributions made in 2019 or 2018.
|
|
|
|
|
|
The Plan provides that unless the participant affirmatively elects otherwise, the participant’s compensation will automatically be reduced by 3%, which will be considered to be the Participant’s salary reduction election.
|
|
|
|
|
|
Participant Accounts
|
|
|
|
|
|
Participants direct both their contributions and employer contributions into various investment options offered by the Plan which include a choice of mutual funds and the common stock of Enzo Biochem, Inc. Each participant’s account is credited with the participant’s contribution and allocations of (a) the Company’s matching contribution and non-elective employer contribution, (b) Plan earnings and c) charged with an allocation of administrative expenses. Allocations are based on participant compensation, account balances or specific participant transactions, as defined. The benefit to which a participant is entitled is the benefit that can be provided from the participant’s vested account.
|
|
|
The Plan allows a participant to elect
to classify all or part of his or her elective deferrals as a Roth 401(k) deferral.
|
|
|
|
|
|
Vesting
|
|
|
|
|
|
Participants’ contributed funds arising from salary reductions and the earnings thereon, are fully vested at all times. Vesting in the Company’s discretionary matching contribution and non-elective employer contribution and earnings thereon, is ratable over four years of service.
|
|
|
|
|
|
Forfeitures
|
|
|
|
|
|
Forfeited non-vested amounts may be used to reduce the Company’s future contributions to the Plan or pay Plan expenses. During the year ended December 31, 2019, forfeitures of $60,831 were used to pay Plan expenses. Forfeited non-vested accounts available at December 31, 2019 and 2018 were $33,316 and $66,473, respectively.
|
ENZO BIOCHEM, INC.
SALARY REDUCTION PROFIT SHARING PLAN
Notes to Financial Statements
|
NOTE 1:
|
PLAN DESCRIPTION (continued)
|
|
|
|
|
|
Notes Receivable from Participants
|
|
|
|
|
|
Notes receivable from participants are measured at their unpaid principal balance plus any accrued but unpaid interest. Participants may borrow from their accounts a minimum of $1,000 up to a maximum of 50% of their vested account balance or $50,000. Participants are entitled to borrow from their account for a maximum loan term of five years unless the proceeds are used to acquire a principal residence in which case it may exceed five years. The loans, classified as Notes Receivable from Participants, are secured by the participant’s vested account balance and bear a reasonable rate of interest, ranging from 4.5% to 5.0% at December 31, 2019. Principal and interest is paid ratably through payroll deductions. Delinquent notes receivable from participants are reclassified as distributions based upon the terms of the Plan document. Related fees are recorded as administrative expenses and are expensed when they are incurred.
|
|
|
|
|
|
Payment of Benefits
|
|
|
|
|
|
On termination of service due to death, disability or retirement, participants may elect to receive an amount equal to the value of the vested interest in their account in a lump sum amount. For termination of service due to other reasons, a participant may receive the value of the vested interest in their account as a lump sum distribution. Benefits are payable in the form of cash or Company common stock.
|
|
|
|
|
|
Plan Expenses
|
|
|
|
|
|
Substantially all expenses incurred
in connection with the administration of the Plan are paid by the Plan. Costs associated with participant loans are paid by participants.
|
|
|
|
|
NOTE 2:
|
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
|
|
|
|
|
|
Basis of Accounting
|
|
|
|
|
|
The Plan’s financial statements have
been prepared in conformity with accounting principles generally accepted in the United States of America and under the accrual
basis method of accounting.
Payment of Benefits
Benefits are recorded when paid.
Use of Estimates
The preparation of the financial statements in conformity with
accounting principles generally accepted in the United States of America requires management to make estimates and assumptions
that affect reported amounts of net assets available for benefits at the date of the financial statements and the accompanying
footnotes and the changes in net assets available for benefits during the reporting period and when applicable disclosures of contingent
assets and liabilities at the date of the financial statements. Actual results could differ from those estimates.
|
|
|
Investment Valuation and Income Recognition
The Plan’s investments are stated
at fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date. See Note 3 for discussion of fair value measurements.
|
|
|
Interest income is recorded on the accrual
basis. Dividends are recorded on the ex-dividend date. Investment earnings are reinvested in the respective funds. Investment earnings
include the Plan’s proportionate share of realized gains and losses on the disposal of investments, and appreciation or depreciation
in the fair value of the underlying investments. All purchases and sales are recorded on a trade date basis.
|
ENZO BIOCHEM, INC.
SALARY REDUCTION PROFIT SHARING PLAN
Notes to Financial Statements
|
NOTE 2:
|
SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES (continued)
|
|
|
|
|
|
The Plan presents in the statement of changes
in net asset available for benefits, the net appreciation/depreciation in fair value of its investments, which consists of the
realized gains or losses and the unrealized appreciation/depreciation on those investments.
|
|
NOTE 3:
|
FAIR VALUE MEASUREMENTS
|
|
|
The Financial Accounting Standards Board’s
(“FASB”), Accounting Standards Codification (“ASC” 820), Fair Value Measurements and Disclosures,
provides a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation
techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for
identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). The
three levels of the fair value hierarchy under ASC 820 are described as follows:
|
|
|
Level 1 - Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Plan has the ability to access.
|
|
|
|
|
|
Level 2 - Inputs to the valuation methodology include: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in inactive markets; inputs other than quoted prices that are observable for the assets or liability; inputs that are derived principally from or corroborated by observable market data by correlation or other means.
|
|
|
|
|
|
If the asset or liability has a specified (contractual) term, the level 2 Input must be observable for substantially the full term of the asset or liability.
|
|
|
|
|
|
Level 3 - Inputs to the valuation methodology are unobservable and significant to the fair value measurements.
|
|
|
|
|
|
The asset or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.
|
|
|
|
|
|
Following is a description of the valuation methodologies used
for assets measured at fair value. There have been no changes in the methodologies used at December 31, 2019 and 2018.
Mutual funds –
Valued at the daily closing price as reported by the fund. Mutual funds held by the Plan are open-ended mutual funds that are
registered with the Securities and Exchange Commission. These funds are required to publish their daily net asset value (“NAV”)
and to transact at that price. The mutual funds held by the Plan are deemed to be actively traded.
|
ENZO BIOCHEM, INC.
SALARY REDUCTION PROFIT SHARING PLAN
Notes to Financial Statements
|
NOTE 3:
|
FAIR VALUE MEASUREMENTS (continued)
|
Common
stocks – Enzo Biochem, Inc. – Valued at the closing price reported on the active market on which the individual securities
are traded.
The methods described may produce a fair value calculation
that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the Plan believes
its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions
to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting
date.
The following tables sets forth by level, within
the fair value hierarchy, the Plan’s investments as of December 31:
|
|
|
Assets at Fair Value as of
|
|
|
|
|
December 31, 2019
|
|
|
December 31, 2018
|
|
|
|
|
Level 1
|
|
|
Level 1
|
|
|
Mutual funds
|
|
|
32,523,374
|
|
|
|
26,750,617
|
|
|
Common stock-Enzo Biochem, Inc.
|
|
|
2,961,454
|
|
|
|
2,516,906
|
|
|
|
|
$
|
35,484,828
|
|
|
$
|
29,267,523
|
|
Changes in Fair Value Levels
The availability of observable
market data is monitored to assess the appropriate classification of financial instruments within the fair value hierarchy. Changes
in economic conditions or model-based valuation techniques may require the transfer of financial instruments from one fair value
level to another.
|
NOTE 4:
|
RIGHT TO TERMINATE PLAN
|
|
|
|
|
|
Although it has not expressed any intent
to do so, the Company has the right under the Plan to discontinue its contributions at any time and to terminate the Plan subject
to the provisions of ERISA. In the event of Plan termination participants would become 100% vested in their Company contributions.
|
|
NOTE 5:
|
TAX STATUS
|
|
|
|
|
|
The Plan has adopted the Fidelity Management
and Research Company Volume Submitter plan. On March 31, 2014 the Internal Revenue Service stated in an advisory letter that the
Volume Submitter adopted by the Plan, as then assigned, was in compliance with the applicable requirements of the Internal Revenue
Code and therefore, the related trust is exempt from taxation. The Plan has been amended since receiving the letter. However, the
Plan administrator believes that the Plan is currently designed and being operated in compliance with the applicable requirements
of the Internal Revenue Code. Therefore, the Plan administrator believes that the Plan is qualified and the related trust is tax-exempt.
Accounting principles generally accepted
in the United States of America require plan management to evaluate tax positions taken by the Plan and recognize a tax liability
if the plan has taken an uncertain position that more likely than not would not be sustained upon examination by a government authority.
The plan administrator has analyzed the tax positions taken by the Plan, and has concluded that as of December 31, 2019, there
are no uncertain positions taken or expected to be taken that would require recognition of a liability or disclosure in the financial
statements. The Plan is subject to routine examination by taxing jurisdictions; however, there are currently no examinations for
any tax periods in progress.
|
ENZO BIOCHEM, INC.
SALARY REDUCTION PROFIT SHARING PLAN
Notes to Financial Statements
|
NOTE 6:
|
RELATED PARTY AND PARTY IN INTEREST TRANSACTIONS
|
|
|
|
|
|
During 2019, the Plan purchased 325,057 shares of common stock of the Plan sponsor, at market prices totaling $862,317 and sold 104,390 shares of common stock at market prices totaling approximately $345,273. At December 31, 2019 and 2018, the Plan held Enzo Biochem, Inc. common stock with a fair value of $2,961,454 and shares owned of 1,126,028 and a fair value of $2,516,906 and shares owned of 905,362, respectively.
|
|
|
|
|
|
Fidelity Management Trust Company (“FMTC”)
is the trustee and recordkeeper of the Plan. Certain Plan investments are shares of mutual funds managed by affiliates of FMTC.
Therefore, these transactions qualify as Party-in-interest transactions. Fees paid by the Plan for the investment management services
are included in net appreciation in fair value of investments.
|
|
|
Fees paid by the Plan to FMTC
amounted to $15,054 for the year ended December 31, 2019. In addition the Plan paid for legal, advisory and auditing fees amounting
to $60,658 for the year ended December 31, 2019.
|
|
|
|
|
NOTE 7:
|
RISKS AND UNCERTAINTIES
|
|
|
|
|
|
The Plan invests in various investment
securities. Investment securities are exposed to various risk such as interest rate, market, and credit risks. Due to the level
of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment
securities will occur in the near term and that such changes could materially affect participants’ account balances and the
amounts reported in the statements of net assets available for benefits.
Volatility in the financial markets may
significantly impact the subsequent valuation of the Plan’s investments. Accordingly, the valuation of investments at December
31, 2019 may not necessarily be indicative of amounts that could be realized in a current market exchange.
The extent of the impact of the
coronavirus (“COVID-19”) outbreak on the financial performance of the Plan’s investments will depend on future developments,
including the duration and spread of the outbreak and related advisories and restrictions and the impact of COVID-19 on the financial
markets and the overall economy, all of which are highly uncertain and cannot be predicted. If the financial markets and/or the
overall economy are impacted for an extended period, the Plan’s investment results may be materially adversely affected. COVID-19
poses risks to the Company as well, given that such public health epidemics, if sustained, could impact Company employees, customers,
supply chain and production in affected regions. Additionally, a prolonged widespread epidemic could adversely impact global economies
and financial markets resulting in an economic downturn that may impact demand for the Company’s products and services. Such impacts
could adversely affect Company profitability, cash flows, financial results, and the ability to make required Plan contributions.
At this point, the extent to which the coronavirus may impact the Company’s financial results is uncertain. The Company expects
its COVID-19 related products and services to partially offset revenue declines. Enzo has publicly announced that it has applied
its technical expertise in molecular diagnostics and serological testing to develop next generation COVID-19 and related antibody
testing options. Enzo’s innovations include virus-inactivating specimen collection media to lessen transmission risks for
healthcare providers and clinical laboratory personnel, the development of more relevant positive controls for the tests, and
improved sensitivity. However, it is too early to determine the significance of any positive impact from increased testing and
the Company’s proprietary product offerings on revenue, profitability and cash flow.
|
ENZO BIOCHEM, INC.
SALARY REDUCTION PROFIT SHARING PLAN
Notes to Financial Statements
|
NOTE 8:
|
MUTUAL FUND FEES
|
|
|
|
|
|
Investments in mutual funds are
subject to sales charges in the form of front-end loads, back-end loads or 12b-l fees. 12b-l fees, which are ongoing fees allowable
under Section 12b-1 of the Investment Company Act of 1940, are annual fees deducted to pay for marketing and distribution costs
of the funds. These fees are deducted prior to the allocation of the Plan’s investment earnings activity, and thus not separately
identifiable as an expense.
|
|
|
|
|
NOTE 9:
|
SUBSEQUENT EVENTS
|
|
|
|
|
|
The Coronavirus, Aid, Relief, and Economic Security (CARES) Act was
signed into law on March 27, 2020. The Act includes an optional change related to the delay of participant loan repayments. The
Act permits plan sponsors to allow qualifying participants to delay loan repayments that would otherwise be due between March 27,
2020 and December 31, 2020. All loan repayments due from the date the participant requests deferment through December 31, 2020
will be deferred. The Plan elected to adopt this optional change related to the delay of loan repayments.
|
ENZO BIOCHEM, INC.
SALARY REDUCTION PLAN
Schedule H, Line 4i
Schedule of Assets (Held at End of Year)
E.I.N. # 13-2866202
Plan # 001
December 31, 2019
|
(a)
|
|
Identity of Issue, Borrower, Lessor or Similar Party (b)
|
|
Description
of Investment Including Maturity Date, Rate of Interest, Collateral, Par or Maturity Value (c)
|
|
Current Value (e)
|
|
|
*
|
|
Enzo Biochem, Inc.
|
|
Common Stock
|
|
$
|
2,961,454
|
|
|
|
|
Pimco Total Return
|
|
Mutual Fund
|
|
|
300,051
|
|
|
|
|
INVS DIVRS DIVD R5
|
|
Mutual Fund
|
|
|
259,492
|
|
|
|
|
NB Genesis
|
|
Mutual Fund
|
|
|
503,896
|
|
|
|
|
JPM Mid Cap Growth A
|
|
Mutual Fund
|
|
|
478,318
|
|
|
|
|
WF SPL Small Cap Val A
|
|
Mutual Fund
|
|
|
576,512
|
|
|
|
|
Columbia Acorn International Select
|
|
Mutual Fund
|
|
|
331,306
|
|
|
|
|
TRP Div Growth Adv
|
|
Mutual Fund
|
|
|
218,220
|
|
|
|
|
WFA Small Cap Growth Adm
|
|
Mutual Fund
|
|
|
169,069
|
|
|
|
|
Parnassus Mid Cap
|
|
Mutual Fund
|
|
|
186,950
|
|
|
*
|
|
Fidelity Contrafund
|
|
Mutual Fund
|
|
|
2,739,924
|
|
|
*
|
|
Fidelity Capital & Income
|
|
Mutual Fund
|
|
|
825,044
|
|
|
*
|
|
Fidelity Government Income
|
|
Mutual Fund
|
|
|
273,416
|
|
|
*
|
|
Fidelity International Discovery
|
|
Mutual Fund
|
|
|
158,863
|
|
|
*
|
|
Fidelity Emerging Markets
|
|
Mutual Fund
|
|
|
245,458
|
|
|
*
|
|
Fidelity Growth Discovery
|
|
Mutual Fund
|
|
|
2,387,380
|
|
|
*
|
|
Fidelity Freedom Income
|
|
Mutual Fund
|
|
|
582
|
|
|
*
|
|
Fidelity Freedom Inc
|
|
Mutual Fund
|
|
|
115,906
|
|
|
*
|
|
Fidelity Freedom 2010
|
|
Mutual Fund
|
|
|
549,373
|
|
|
*
|
|
Fidelity Freedom 2020
|
|
Mutual Fund
|
|
|
3,086,595
|
|
|
*
|
|
Fidelity Freedom 2030
|
|
Mutual Fund
|
|
|
3,651,331
|
|
|
*
|
|
Fidelity Ext Market Inx
|
|
Mutual Fund
|
|
|
696,836
|
|
|
*
|
|
Fidelity International Index
|
|
Mutual Fund
|
|
|
202,082
|
|
|
*
|
|
Fidelity Govt MMKT
|
|
Mutual Fund
|
|
|
952,862
|
|
|
*
|
|
Fidelity 500 Index
|
|
Mutual Fund
|
|
|
2,003,290
|
|
|
*
|
|
Fidelity Freedom 2040
|
|
Mutual Fund
|
|
|
1,726,042
|
|
|
*
|
|
Fidelity Freedom 2005
|
|
Mutual Fund
|
|
|
87,982
|
|
|
*
|
|
Fidelity Freedom 2015
|
|
Mutual Fund
|
|
|
2,543,763
|
|
|
*
|
|
Fidelity Freedom 2025
|
|
Mutual Fund
|
|
|
3,101,375
|
|
|
*
|
|
Fidelity Freedom 2035
|
|
Mutual Fund
|
|
|
1,924,667
|
|
|
*
|
|
Fidelity Freedom 2045
|
|
Mutual Fund
|
|
|
959,413
|
|
|
*
|
|
Fidelity Freedom 2050
|
|
Mutual Fund
|
|
|
598,243
|
|
|
*
|
|
Fidelity US Bond IDX Adv
|
|
Mutual Fund
|
|
|
255,120
|
|
|
*
|
|
Fidelity Freedom 2055
|
|
Mutual Fund
|
|
|
288,039
|
|
|
*
|
|
Fidelity Freedom 2060
|
|
Mutual Fund
|
|
|
124,505
|
|
|
*
|
|
Fidelity Freedom 2065
|
|
Mutual Fund
|
|
|
418
|
|
|
*
|
|
Fidelity Cash Reserves
|
|
Mutual Fund
|
|
|
1,051
|
|
|
*
|
|
Notes receivable - participants
|
|
4.5% - 5.0%
|
|
|
766,493
|
|
|
|
|
|
|
|
|
$
|
36,251,321
|
|
* Party-in-interest, as defined by ERISA
SIGNATURE
Pursuant to the requirements of the Securities Exchange
Act of 1934, a trustee of the below named employee benefit plan has duly caused this annual report to be signed on its behalf by
the undersigned hereunto duly authorized.
Enzo Biochem, Inc. Salary Reduction Profit Sharing
Plan
|
Date: August 12, 2020
|
|
|
|
|
|
/s/ Barry Weiner
|
|
|
By: Barry Weiner
|
|
|
Trustee
|
|
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference
in the Registration Statement of Enzo Biochem, Inc. on Form S-8 (File No. 333-197028 and 333-236958) of our report dated August
12, 2020 on our audits of the financial statements of the Enzo Biochem, Inc. Salary Reduction Profit Sharing Plan as of December
31, 2019 and 2018 and for the year ended December 31, 2019, and supplemental schedule as of December 31, 2019, which report is
included in this Annual Report on Form 11-K to be filed on or about August 12, 2020.
/s/EisnerAmper LLP
EISNERAMPER LLP
New York, New York
August 12, 2020
12
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Apr 2023 to Apr 2024
